[Correlations between the p-Akt-mTOR-p70S6K pathway and clinicopathological features or chemoresistance of ovarian cancer].
To study the relationship between alpha seine/threonine-protein kinase (p-Akt)-serine/threonine-protein kinase (mTOR)-ribosomal protein S6 kinase (p70S6K) signaling pathway and clinicopathological features or chemoresistance of ovarian cancer. Methods: We checked the p-Akt, mTOR and p70S6K protein levels in 18 tissues with chemoresistance or 25 with chemosensitivity of ovarian cancer by immunohistochemistry technique, and analyzed the relationship between those proteins and clinicopathological features or chemoresistance of ovarian cancer. Results: The levels of p-Akt protein in ovarian serous carcinoma, mucinous carcinoma and endometrioid carcinoma were 77.14%, 50.00% and 66.67%, respectively, with no significant difference (P>0.05). The levels of these proteins in well-middle differentiated carcinoma and low differentiated carcinoma were 73.33% and 75.00%, respectively, with no significant difference (P>0.05). The levels of these proteins in I-II stage carcinoma, and III-IV stage carcinoma were 18.18% and 93.75%, respectively, with significant difference (P<0.05). The levels of mTOR protein in ovarian serous carcinoma, mucinous carcinoma and endometrioid carcinoma were 77.14%, 100.00% and 83.33%, respectively, with no significant difference (P>0.05). The levels of this protein in well-middle differentiated carcinoma and low differentiated carcinoma were 80.00% and 78.57%, respectively, with no significant difference (P>0.05). The levels of this protein in I-II stage carcinoma, and III-IV stage carcinoma were 27.27% and 96.88%, respectively, with significant difference (P<0.05). The levels of p70S6K protein in ovarian serous carcinoma, mucinous carcinoma and endometrioid carcinoma were 80.00%, 100.00% and 100.00%, respectively, with no significant difference (P>0.05). The levels of this protein in well-middle differentiated carcinoma and low differentiated carcinoma were 93.33% and 78.57%, respectively, with no significant difference (P>0.05). The levels of this protein in I-II stage carcinoma, and III-IV stage carcinoma were 45.45% and 96.88%, respectively, with significant difference (P<0.05). The levels of p-Akt protein in tissue of chemoresistance and chemosensitivity of ovarian cancer were 88.89% and 64.00%, respectively, with significant difference (P<0.05). The levels of mTOR protein in tissue of chemoresistance and chemosensitivity of ovarian cancer were 94.44% and 68.00%, respectively, with significant difference (P<0.05). The levels of p70S6K protein in tissue of chemoresistance and chemosensitivity of ovarian cancer were 100.00% and 72.00%, respectively, with significant difference (P<0.05). Conclusion: The p-Akt-mTOR-p70S6K signaling pathway may take part in invasion and metastasis of ovarian cancer. The up-regulation of these proteins may be associated with the chemoresistance of ovarian cancer, and these proteins may have potential to be the prognostic markers for the chemoresistance of ovarian cancer.